Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 20, 435-442, May 1, 1960]
© 1960 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ellison, R. R.
Right arrow Articles by Krakoff, I. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ellison, R. R.
Right arrow Articles by Krakoff, I. H.

Clinical Investigations of 6-Azathymine A Thymine Analog*

Rose Ruth Ellison, Charlotte T. C. Tan, M. Lois Murphy and Irwin H. Krakoff

( Division of Clinical Chemotherapy, Sloan-Kettering Institute for Cancer Research; Departments of Pediatrics and Medicine, Memorial and James Ewing Hospitals; and Cornell University Medical College, New York, N.Y.)

Twenty-four patients received azathymine. All fourteen children and two of the adults had acute leukemia; the other adults had a variety of solid tumors. All of the children had previously responded to Methotrexate and had then become resistant to it. Azathymine did not produce any improvement in any patient.

The hepatotoxic effect of azathymine was striking in the adults and occurred in the absence of objective regression of the neoplastic disease. Liver damage also occurred in one child.

Azathymine exerts a specific renal effect, causing hyperuricemia associated with a decrease in the excretion of uric acid. This occurs early in the course of therapy and with doses that do not cause liver function changes.

* These studies were supported by research grants C-1889, CY-2329, and CY-3215 from the National Cancer Institute of the National Institutes of Health, Public Health Service; the American Cancer Society, the Damon Runyon Memorial Fund for Cancer Research, the Lasker Foundation, the Grant Foundation, and the Black-Stevenson Fund.

Received 9/25/59.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1960 by the American Association for Cancer Research.